# Thymosin α1

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/thymosin-alpha-1 (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: The most clinically validated immunomodulatory peptide, approved in 35+ countries for hepatitis, sepsis, and immune deficiency.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/thymosin-alpha-1

\*\*Immune Support · Strong Evidence · Research Only\*\* ### Thymosin Alpha-1 (Zadaxin) The most clinically validated immunomodulatory peptide, approved in 35+ countries for hepatitis, sepsis, and immune deficiency. ### Description Thymosin Alpha-1 (Tα1, Zadaxin) is a 28-amino acid peptide naturally produced by the thymus gland, first isolated and characterized by Dr. Allan Goldstein in the 1970s. It is the most extensively studied and clinically validated immunomodulatory peptide in the world, with regulatory approval in over 35 countries for the treatment of hepatitis B, hepatitis C, and various immune deficiency conditions. Tα1 is the primary active component of thymosin fraction 5, the thymic extract that was found to restore immune function in thymectomized animals. It has been studied in over 100 clinical trials covering hepatitis, cancer, sepsis, COVID-19, and vaccine adjuvancy. In the COVID-19 pandemic, Observational studies from China and Italy reported associations with lower mortality and ICU admission. These were not randomised, and the finding has not been confirmed in a controlled trial.. Its broad immunomodulatory effects — enhancing both innate and adaptive immunity while also having anti-inflammatory properties — make it uniquely valuable for conditions involving immune dysregulation. ### Key Characteristics - \*\*Molecular Formula:\*\* C129H215N33O55 - \*\*Molecular Weight:\*\* 3108.3 Da - \*\*Half-Life:\*\* ~2 hours - \*\*Administration Routes:\*\* Subcutaneous injection - \*\*Typical Dose:\*\* 1.6 mg - \*\*Frequency:\*\* 2x per week ### Investigated Benefits - Enhanced T-cell function - Improved vaccine response - Hepatitis B and C treatment support - Studied in sepsis (phase 3 trial found no mortality benefit) - COVID-19 severity reduction \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action “The most clinically validated immunomodulatory peptide, approved in 35+ countries for hepatitis, sepsis, and immune deficiency.” Thymosin Alpha-1 acts primarily through Toll-like receptor 9 (TLR9) on dendritic cells and macrophages, triggering MyD88-dependent signaling that activates NF-κB and IRF7, leading to the production of type I interferons (IFN-α, IFN-β) and pro-inflammatory cytokines that initiate innate immune responses. In the adaptive immune system, Tα1 promotes the maturation and differentiation of naïve T-cells into Th1 effector cells (producing IFN-γ and IL-2), enhances cytotoxic T-lymphocyte (CTL) activity, and increases the expression of MHC class I and II molecules on antigen-presenting cells, improving antigen presentation. It also enhances natural killer (NK) cell cytotoxicity and promotes dendritic cell maturation. Paradoxically, Tα1 also has anti-inflammatory effects in hyperinflammatory states, reducing excessive cytokine production (the “cytokine storm”) through regulatory T-cell (Treg) induction — this dual immunomodulatory capacity explains its efficacy in both immunodeficiency and hyperinflammatory conditions. ### Dosing Protocol - \*\*Typical Dose:\*\* 1.6 mg - \*\*Frequency:\*\* every other day - \*\*Cycle Length:\*\* 6–12 months (chronic) or 4–8 weeks (acute) - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* Standard clinical dose is 1.6 mg SC twice weekly. For acute immune support, some practitioners use daily dosing for 2–4 weeks. ### Reconstitution Guide Add 1 mL bacteriostatic water to 1.6 mg vial → 1.6 mg/mL ### Storage Information Lyophilized: refrigerate. Reconstituted: refrigerate and use within 24 hours. ### Quality & Sourcing Standards When sourcing Thymosin α1 for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Approved in 35+ countries for hepatitis B, hepatitis C, and immune deficiency 2. Sepsis trials have not shown a survival benefit. The ETASS trial (2013) reported 26.0% vs 35.0% mortality, p = 0.062 — not statistically significant. The larger TESTS phase 3 trial (2025, n = 1,106) reported 23.4% vs 24.1%, p = 0.82, concluding no effect. 3. Reduced COVID-19 severity in multiple studies 4. Over 100 clinical trials completed ### Evidence Level \*\*Strong Evidence\*\* Strong for hepatitis B/C and immune deficiency, where approval rests on randomised controlled trials. Evidence for sepsis is negative in the largest trial to date. COVID-19 data are observational. Use in longevity protocols is not supported by trial evidence. ### Compatible Peptides Peptides commonly used alongside Thymosin α1 for synergistic effects. - \*\*BPC-157\*\* (Recovery & Repair): A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems. - \*\*Epithalon\*\* (Longevity & Anti-Aging): A tetrapeptide derived from the pineal gland that activates telomerase and has demonstrated lifespan extension in multiple animal models. ### Protocols Featuring Thymosin α1 - \*\*Longevity Protocol:\*\* Anti-aging, telomere support, and cellular rejuvenation - \*\*Immune Optimization Protocol:\*\* Comprehensive immune system enhancement ### Quick Reference - \*\*Category:\*\* Immune Support - \*\*Status:\*\* Research Only - \*\*Dose:\*\* 1.6 mg - \*\*Frequency:\*\* 2x per week - \*\*Cycle:\*\* 6–12 months (chronic) or 4–8 weeks (acute) ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.